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Summary 
Background: Cathepsin S (CTSS) is a cysteine protease
involved in atherogenesis. We compared the plasma CTSS
as well as other biomarkers of atherosclerosis in patients
with abdominal aortic aneurysms (AAA) and aortoiliac
occlusive disease (AOD), aiming to identify the underlying
pathogenic mechanisms of the disease development. Also,
we hypothesised that the level of plasma CTSS simultaneously
increases with a decrease of plasma high-density lipo -
protein cholesterol (HDL-C) values. 
Methods: 33 patients with AAA and 34 patients with AOD
were included in this study. 
Results: There was no difference in the level of plasma
CTSS between the two analysed groups (p=0.833). In the
patients with AAA, the plasma CTSS was correlated with
HDL-C (r = -0.377, p = 0.034) and total bilirubin (r =-
0.500, p = 0.003) while, unexpectedly, it was not correlated
with cystatin C (Cys C) (r =0.083, p = 0.652). In the patients
with AOD, the plasma CTSS correlated with triglycerides
Kratak sadr`aj
Uvod: Katepsin S (CTSS) je cisteinska proteaza uklju~ena u
aterogenezu. Uporedili smo plazmatski CTSS kao i druge
biomarkere ateroskleroze kod pacijenata sa aneurizmom
abdominalne aorte (AAA) i aorto ilija~nom oklu ziv nom bo -
le{}u (AOD) sa ciljem da se identifikuju osnovni patogeni
mehanizmi razvoja bolesti. Tako|e, pretpostavili smo da se
nivo plazmatskog CTSS isto vremeno pove}ava sa sma nje -
njem vrednosti holesterola plazmatskih lipo pro teina visoke
gustine (HDL-C).
Metode: Ova studija je obuhvatila 33 pacijenta sa AAA i 34
pacijenta sa AOD.
Rezultati: Nije bilo razlike u nivou plazmatskog CTSS izme -
|u dve analizirane grupe (p = 0,833). Kod pacijenata sa AAA,
plazmatski CTSS je bio u korelaciji sa HDL-C (r = -0,377,
p = 0,034) i ukupnim bilirubinom (r = - 0,500, p = 0,003),
dok, neo~ekivano, nije bio u korelaciji sa cista tinom C (Cys
C) (r = 0,083, p = 0,652). Kod pacijenata sa AOD, plaz -
matski CTSS je bio u korelaciji sa trigliceridima (r = 0,597,
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Introduction
Studies demonstrate that abdominal aortic
aneurysms (AAA) and aortoiliac occlusive disease
(AOD) are related to underlying atherosclerotic
disease (1, 2). However, consequences of these
diseases are different. AAA results in abdominal aorta
dilatation while AOD results in occlusion of main
arteries in the pelvis. 
A recent study by Peshkova et al. (3) shows that
there are several theories regarding the AAA etiology.
One is that atherosclerosis-driven changes in the
aortic wall underlie AAA pathology, and the inflam -
matory mechanisms promoting atherosclerosis
contribute to AAA. The second possibility is that dif -
ferent risk factors promote AAA and atherosclerosis
separately, and they thus develop independently
without greatly influencing one another. The third
possibility is that the same risk factors promote both
AAA and atherosclerosis via similar mechanisms,
although additional factors are required for AAA
induction. 
Cathepsin S (EC 3.4.22.27) (CTSS) is a cysteine
protease involved in atherogenesis (4–6). CTSS is
synthesised in macrophages, smooth muscle cells,
and endothelial cells and when released extra -
cellularly it exerts elastolytic and collagenolytic
activities leading to elastic lamina degradation,
plaque rupture and necrotic core development (7, 8).
Studies show that CTSS levels are increased in human
and animal atheroma, in the abdominal aortic
aneurysm (9) but not in non-atherosclerotic arteries
(4, 10). 
Since several theories are based on the fact that
different risk factors promote atherosclerosis, the
focus of this paper was on markers associated with
CTSS in patients with AAA and AOD. Cystatin C (Cys
C) is an endogenous inhibitor of cysteine peptidases
also known as a marker for atherosclerosis (11). In
vitro studies indicate that CTSS may have an impact
on lipoproteins metabolism. Incubation of HDL3
(high-density lipoprotein), isolated by ultra centri -
fugation, with CTSS led to a rapid loss of pre -HDL
and a reduced cholesterol efflux from macrophages
(12). Today, antioxidative and anti-inflammatory
vasoprotective effects of HDL are well known (13–
15). In addition to this, the serum total bilirubin
concentration is inversely associated with a risk in
cardiovascular disease (16, 17) because the total
bilirubin is a strong antioxidant in the human body
(18, 19). 
We analysed the plasma CTSS and other
markers of atherosclerosis in patients with AAA and
AOD, aiming to identify the underlying pathogenic
mechanisms of the disease development. Also, our
study was designed to examine whether the level of
CTSS was higher if the level of HDL-C was lower in
the entire group of patients.
Materials and Methods
Subjects and blood sampling
33 patients with AAA and 34 patients with AOD
were included in this study. The patients consecutively
enrolled from the Department of Surgery, at the
University Clinical Centre of the Republic of Srpska,
Banja Luka, Bosnia and Herzegovina. The collection
period for the samples was from May 2014 to July
2015. The diagnosis of AAA and AOD was set up by
using abdominal ultrasound and magnetic resonance
angiography and based on a detailed clinical
examination. Including criteria for the study were
patients with AAA and AOD who would be treated
surgically and who would have an elective surgical
program. Patients with AAA and AOD operated on as
urgent surgical cases, and those with previous surgery
as well as patients with aneurysms at other locali -
sation were excluded from the study. Some of them
received statins and ACE inhibitors (angiotensin II or
receptor antagonist). The study was approved by the
National Ethics Committee, and all patients con -
sented to participate. Blood was collected from the
antecubital vein at the time of the preparation for
surgery.
(r = 0.597, p< 0.001), only. When the patients were
divided according to HDL-C (with HDL-C ≤0.90 and HDL-
C >0.90 mmol/L), the plasma CTSS values differed
among these groups (31.27 vs.25.61 mg/L, respectively,
p<0.001). 
Conclusions: These results provide the first evidence that
CTSS negatively correlated with HDL-C and bilirubin in
patients with AAA. It is possible that differences in the
association of the CTSS and other markers of athero -
sclerosis can determine whether atherosclerotic aorta will
develop dilatation or stenosis. 
Keywords: abdominal aortic aneurysm, cathepsin S,
cystatin C, HDL-C 
p <0.001). Kada su pacijenti podeljeni prema HDL-C (sa
HDL-C ≤ 0,90 i HDL-C > 0,90 mmol/L), vrednosti plaz -
mat skog CTSS su se razlikovale me|u grupama (31,27
naspram 25,61 mg/L, respektivno, p < 0,001).
Zaklju~ak: Ovi rezultati pru`aju prvi dokaz da je CTSS
negativno povezan sa HDL-C i bilirubinom kod pacijenata
sa AAA. Pretpostavka je da se na osnovu razlike u aso -
cijaciji CTSS-a i drugih markera ateroskleroze mo`e utvrditi
da li }e ateroskleroza aorte dovesti do dilatacije ili stenoze.
Klju~ne re~i: aneurizma abdominalne aorte, katepsin S,
cistatin C, HDL-C 
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Methods 
The combination of 2B4 MAb and 1E3 MAb
(Krka, d.d., Ljubljana, Slovenia) was used to optimise
sandwich ELISA. Both antibodies recognise mature
and pro-forms of CTSS. Microtitre plates were coated
with 10 mg mL–1 of 2B4 MAb in 0.01 mol/L carbo -
nate/bicarbonate buffer, pH 9.4 at 4 °C. After blocking
(2% BSA-PBS, 150 mL well–1), the samples or CTSS
standards were added (100 mL well–1). After 2 h of
in cubation, wells were washed and filled with 1E3
MAb conjugated with HRP. After further 2 h of in -
cubation at 37 °C 200 mg well–1 of peroxidase
substrate 3,3,5,5-tetramethylbenzidine (TMB, Sigma)
0.012% H2O2 was added. After 15 minutes, the
reaction was stopped by adding 50 mL of 2 mol/L
H2SO4. The amount of degraded substrate, as a
measure of bound immune-complexed CTSS, was
determined by absorbance at 450 nm, and the con -
centration of CTSS calculated from the calibration
curve (20). Samples were processed in the same run.
Cys C, HDL-C, triglycerides (TG), low-density lipo -
protein cholesterol (LDL-C), total bilirubin, Apo A-I,
CRP and alpha-1 antitrypsin were determined by
Cobas 6000 analyser (Roche, Germany), by reagents
from Roche Diagnostics (Roche Diagnostics, Mann -
heim, Germany), according to the manufacturer’s
instructions. We calculated the apoA/HDL-C ratio as
index negatively associated with AAA. Fibrinogen was
determined by the Clauss method (Siemens Health -
care Diagnostics).
Statistical analysis
All calculations were performed using SPSS v.
20.0 (SPSS Inc. Chicago, IL, USA). Numerical data
are shown as a mean ± standard deviation for
normally distributed variables and as a median and
interquartile range for non-normally distributed
variables. Categorical variables are presented as
relative frequencies. Comparisons of the data were
performed by the unpaired Student’s t-test for
normally distributed data, and the Mann-Whitney U-
test was used to compare data with skewed distri -
bution between groups with AAA and AOD. Analysis
of categorical variables was performed using the Chi-
square test. Relations between the variables were
determined using the Spearman rank-order corre -
lation test. Using univariate and multivariate logistic
regression analysis, we examined the predictors of a
low HDL-C level.
Results
Clinical characteristics of the patients have been
summarised in Table I. The groups with AAA (n=33),
and AOD (n=34) did not differ in atherosclerosis risk
factors (age, gender, hypertension, smoking habits,
the presence of diabetes) and therapy (statins, ACE
inhibitors). The youngest person was 46, and the
oldest 82. The abdominal aortic diameter was 3.50
cm minimum and 7.60 cm maximum, median 5.35
cm. The baseline laboratory parameters of our
patients are shown in Table II. From all examined
parameters only, the bilirubin level was significantly
lower in patients with AOD compared to patients with
AAA. On the other hand, fibrinogen, CRP and alpha-
1 antitrypsin had higher levels in patients with AOD.
HDL-C positively correlated with the total
bilirubin (r = 0.423, p = 0.014) and apo A-I (r =
0.799, p<0.001) while it was negatively associated
with CTSS (r = -0.289, p = 0.018), and TG (r = -497,
p<0.001)). In addition, CTSS was positively asso -
ciated with TG (r = 0.359, p = 0.003) levels. We did
not find an association between Cys C and other
parameters. 
In the patients with AAA, the plasma CTSS was
negatively associated with HDL-C (r = -0.377, p =
Table I Clinical characteristics of patients with AAA and AOD.
Continuous variables are presented as mean ± standard deviation and are compared with the Student’s t-test, whereas categorical
variables are presented as relative frequencies and are compared with Chi-square test. Abbreviations: AAA, abdominal aortic




Age (years) 67.45 ± 9.44 65.87 ±7.67 NS
Gender (male) 84.0 % 66.5 % NS
ACE inhibitors 51.51 % 34.37% NS
Statin 9.0 % 9.3 % NS
Hypertension 72.72 % 68.75 % NS
Diabetes 12.12% 15.62 % NS
Smoking 69.69 % 66.66 % NS
0.034) and total bilirubin (r = -0.500, p = 0.003),
while, unexpectedly, it was not correlated with Cys C
(r = 0.083, p = 0.652) and AAA diameter size (r =
0.140, p = 0.469). In addition, HDL-C was positively
correlated with the total bilirubin (r = 0.423, p =
0.014) while it was not correlated with AAA diameter
size. In the patients with AOD, CTSS was positively
associated with TG only (r = 0.597, p<0.001). Also,
the CTSS was not correlated with Cys C (r = -0.035,
p = 0.842).
The patients were divided into two groups
according to HDL-C, i.e. patients with HDL-C £ 0.90
mmol /L (n = 30), also known as high-risk values and
patients with HDL-C > 0.90 mmol/L (n=37). There
was a difference between the two analysed groups
according to the CTSS concentration (Table III). The
CTSS was significantly lower in patients with higher
HDL-C than in patients with a lower HDL-C con -
centration. 
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Table II Laboratory findings of patients with AAA and AOD.




CTSS (mg/L)* 30.82 ± 13.09 29.86 ± 11.70 0.833
CysC (mg/L) 0.93 (0.76/1.13) 0.91 (0.74/1.50) 0.618 
HDL-C (mmol/L)* 1.09 ± 0.35 1.02 ± 0.31 0.328 
Apo A-I (g/L)* 1.28 ± 0.26 1.17 ± 0.29 0.145
Apo A/HDL-C* 1.23 ± 0.26 1.19 ± 0.25 0.501
TG (mmol/L) 1.78 (1.19/2.36) 1.50 (1.11/2.44) 0.689 
LDL-C (mmol/L) 4.00 (2.92/5.20) 3.70 (2.85/4.35) 0.230 
Total bilirubin (mmol/L) 11.30 (8.20/13.70) 8.25 (6.25/9.50) <0.001 
Fibrinogen (g/L) 3.90 (3.10/4.30) 4.45 (4.02/5.75) 0.002
CRP (mg/L) 4.25 (2.10/12.70) 8.45 (3.22/58.77) 0.051
Alpha-1 antitrypsin (g/L) 1.51 (1.28/1.71) 1.69 (1.54/1.98) 0.005
Parameter  Patients with HDL-C £0.90mmol/L, n=30 
Patients with HDL-C >0.90
mmol/L, n=37 p
CTSS (mg/L) 31.27 (26.84/38.33) 25.61 (19.28/30.30) <0.001
Cys C (g/L) 1.08 (0.78/1.32) 0.90 (0.76/1.10) 0.501 
TG (mmol/L) 2.17 (1.80/2.80) 1.30 (1.10/1.90) <0.001 
LDL-C (mmol/L) 3.70 (2.80/4.44) 3.80 (2.90/5.20) 0.291 
Total bilirubin (mmol/L) 8.20 (6.60/11.45) 10.00 (7.90/13.58) 0.070
The values are presented as medians and interquartile range (Q1/Q3). Mann-Whitney U-test was used to compare data between
groups. 
Abbreviations: AAA, abdominal aortic aneurysm; CTSS, cathepsin S; Cys C, cystatin C; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; p, level of significance; TG, triglycerides.
The values are presented as medians and interquartile range (Q1/Q3) or mean ± standard deviation. Mann-Whitney U-test was used to
compare data between groups, except in variable marked with*, where the Student s t-test was used. 
Abbreviations:  AAA, abdominal aortic aneurysm; AOD, aortoiliac occlusive disease;  Apo A-I, apolipoprotein A; CTSS, cathepsin S; Cys
C, cystatin C; CRP, C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; P, level of
significance; TG, triglycerides.
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We performed binary logistic regression analysis
to determine whether examined parameters had the
potential to predict low HDL-C concentrations (≤0.9
mmol/L). Univariate analysis revealed that increased
TG and CTSS were significant predictors of low HDL-
C (Table IV). Furthermore, we explored confounders
that may alter the association between a low HDL-C
and CTSS concentration. The results of multivariate
logistic regression analysis (Table IV) showed a weak
association between the change in CTSS and a low
HDL-C concentration. The association of CTSS with
HDL-C low levels was not independent of TG con -
centrations. 
Discussion
Our understanding of the mechanisms of AAA
formation is still incomplete, indicating the need for
searching novel biomarkers with predictive ability.
This study shows that there was no difference in the
level of plasma CTSS between patients with AAA and
patients with AOD. CTSS was one of the first cysteinyl
cathepsins discovered in human AAA lesions (17). Its
activities in degrading fibronectin, elastin, collagen
and laminin suggest its involvement in AAA formation
and progression (21, 22) strongly. Also, the patients
with atherosclerotic stenosis had significantly higher
serum levels of CTSS than patients without cardio -
vascular complications (15). Nevertheless, we have
shown, for the first time, the negative correlation
between the plasma CTSS level and HDL-C in AAA
patients. Results studies by Spielmann et al. (23)
provide the first evidence that CTSS sequence
variations are associated with two human metabolic
risk factors for cardiovascular diseases: plasma Apo-
A1 and HDL-C concentrations. Based on their
findings, Spielmann et al. (23) suggested that specific
variants of the CTSS gene may play a role in deter -
mining the Apo-A1 and HDL-C profiles and may thus
influence reverse cholesterol transport. Additionally,
CTSS can have a negative effect on reverse chole -
sterol transport by inducing the degradation of lipid-
poor preB-HDL and Apo-A1 (12). Our study greatly
supports the findings of the mentioned studies that
CTSS may have a negative impact on HDL-C meta -
bolism. Also, when we compare CTSS adjustment to
HDL-C, the patients with HDL-C ≤0.90 mmol/L had
significantly higher values of CTSS than patients with
HDL-C >0.90 mmol/L. It is still unclear why some
patients develop an aneurysm and some occlusive
arterial disease, despite similarities underlying the
development of AAA and AOD, including increased
CTSS and decreased HDL-cholesterol. A concomitant
increase of the CTSS level and a decrease of HDL-C
in plasma of patients may suggest a new mechanism
of CTSS-mediated vascular diseases, as well as the
possibility that the same risk factors promote both
AAA and AOD via similar mechanisms, but additional
factors are required for AAA induction. The close
interrelation between the increasing of CTSS level
and the decreasing of HDL-C in plasma in all patients
definitively needs further clarification. This study will
help in further understanding of the biochemical role
of CTSS and HDL-C in vascular disease. 
In addition, we found a negative correlation
between the plasma CTSS level and bilirubin in the
plasma of AAA patients. The reason for this may be
the fact that the apoptotic cell death is caused by
cellular depletion of bilirubin (24) and consequently
increases CTSS in the plasma. Altogether, higher
circu lating levels of CTSS have shown to be
associated with decreased antioxidative activity in AAA
patients. This study indicates that the mechanisms
formation of AAA and AOD are different because we
did not find the same CTSS association with other
parameters in observed groups. It is possible that
differences in the association of the CTSS and other
markers can determine whether atherosclerotic aorta
will develop dilatation or stenosis. 
We should say, that our study is contrary to the
study of Lv et al. (25) where there was a positive
correlation between the plasma CTSS and AAA
diameter size. In our study, a loss of correlation of the
plasma CTSS and AAA diameter size could be the
result of an advanced stage of the disease in our
patients.
Although Burillo et al. (26) recently found a
significant difference in the concentration of HDL-C
among these patients, our study did not confirm this
data (Table II). Yet, it is interesting that we found a
Table IV Odds ratios for examined parameters impact on
the low HDL-C level.
Multivariate logistic regression analysis was used to examine
the predictors of the low HDL-C level. Abbreviations: CI,
confidence interval; CTSS, cathepsin S; Cys C, cystatin C;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; TG, triglycerides; OR, odds
ratio; p, level of significance. 
Unadjusted 
OR (95% CI) p
TG (mmol/L) 2.561 (1.324–4.953) 0.005
LDL-cholesterol
(mmol/L) 0.824 (0.540–1.258) 0.824
Total bilirubin
(mmol/L) 0.990 (0.924–1.061) 0.773
CTSS (mg/L) 1.067 (1.012–1.126) 0.017
Cys C (mg/L) 1.410 (0.422–4.714) 0.557
Adjusted
OR (95% CI) p
CTSS (mg/L) 1.051 (0.997–1.107) 0.065
TG (mmol/L) 2.251 (1.150–4.406) 0.018
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significant difference in the concentration of total
bilirubin between patients with AAA and patients with
AOD, i.e. the plasma total bilirubin concentration was
lower in the plasma of patients with AOD then in AAA
patients. Bilirubin is recognised as a potent anti -
oxidant (18), and lower total bilirubin could mean
higher oxidative stress. In the development of vascular
disease, oxidative stress plays a critical role, and the
subjects with elevated bilirubin levels had a diminished
risk of atherosclerosis (17). The total bilirubin and
HDL-C are strong antioxidants (18, 19), and our
study shows a correlation between these two
biochemical markers in patients with AAA, a similar
correlation was shown in Oda’s study (27).
Likewise, in our study, in the patients with AOD,
the plasma CTSS concentration was significantly
asso ciated with TG, which is an independent athero -
sclerosis risk factor. This is very important information
because a similar correlation was shown in stable
angina patients (28). The exact mechanisms respon -
sible for this remain unclear, but a close interrelation
between the level of CTSS and atherogenic plasma
TG opens new questions about the complex pathways
of vascular diseases. Also, this group of patients
had significantly higher markers of inflammation,
respectively, which are well known to be underlying
factors for atherosclerosis.
The often-described background mechanism
linking Cys C with atherogenesis is that it is a potent
endogenous inhibitor of CTSS (11, 29). In this respect,
we expected the association of decreased Cys C con -
centrations with an increased CTSS. Contrary to our
expectation, in our study, the plasma Cys C con -
centration was not associated with the plasma CTSS,
and it did not correlate with AAA diameter size.
Lindholt et al. (30) showed that the Cys C deficiency
is associated with the progression of small abdominal
aortic aneurysms, but our results did not support this
claim, perhaps because we examined the progressive
phase of the AAA. However, it is difficult to clarify
what influenced the loss of this control mechanism
between proteinase and its inhibitor, but we could
assume that this disbalance played a significant role
in the development of these diseases.
This study has limitations, i.e. it includes a small
sample size and some patients taking the statin and
antihypertensive medications. Nowadays it is not
known whether conventional therapy may influence
the CTSS concentration in atherogenesis. The scarce
studies of statins and CTSS are contrary; one
indicated that the statin treatment did not change
CTSS activity in the wall of the abdominal aortic
aneurysm (31), another indicated that simvastatin
decreased CTSS in CVD (28, 32). ACE inhibitors or
angiotensin II receptor antagonist also decrease CTSS
mRNA and/or activity (33). Undoubtedly, further
studies need to explain the exact drug action
mechanism in the CTSS. 
Conclusion
These results provide the first evidence that
plasma CTSS is associated with HDL-C and bilirubin
in the patients with AAA. Also, the patients with HDL-
C ≤0.90 mmol/L had significantly higher values of
CTSS than patients with HDL-C >0.90 mmol/L.
Likewise, in our study, in the patients with AOD, the
plasma CTSS concentration was significantly asso -
ciated with TG. It is still unclear why some patients
develop an aneurysm and some occlusive arterial
disease, regardless of similarities underlying the
development of AAA and AOD, including increased
CTSS and decreased HDL-cholesterol. It is possible
that differences in the association of the CTSS and
other markers of atherosclerosis may determine
whether atherosclerotic aorta will develop into a
dilatative or stenotic disease.
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